公开(公告)号：EP1812062A2

公开(公告)日：2007-08-01

申请号：EP05820737.4

申请日：2005-10-21

申请人： Merck & Co., Inc. ,  Northwestern University

发明人： ACTON, Paul ,  AN, Zhiqiang ,  BETT, Andrew, J. ,  BREESE, Robert ,  DODSON, Elizabeth, Chen ,  KINNEY, Gene ,  KLEIN, William ,  LAMBERT, Mary, P. ,  LIANG, Xiaoping ,  SHUGHRUE, Paul ,  STROHL, William, R. ,  VIOLA, Kirsten, L. ,  CHANG, Lei

IPC分类号： A61K39/395

CPC分类号： G01N33/5058 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2814 ,  G01N2800/2821

摘要： The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer’s Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer’s Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.

摘要翻译： 本发明涉及差异识别Aβ衍生的可扩散配体（也称为ADDL）的多维构象的抗体。 本发明的抗体可区分阿尔茨海默氏病和对照人脑提取物，并可用于检测ADDLs和诊断阿尔茨海默氏病的方法。 本发明的抗体还阻断ADDL与神经元的结合，ADDL的组装和tau磷酸化，并且可用于预防和治疗与淀粉样蛋白β1-42的可溶性寡聚体相关的疾病的方法。

公开(公告)号：EP1879613A2

公开(公告)日：2008-01-23

申请号：EP06751930.6

申请日：2006-05-01

申请人： Merck & Co., Inc.

发明人： GARSKY, Victor, M. ,  JOYCE, Joseph, G ,  KELLER, Paul, M. ,  KINNEY, Gene ,  LIANG, Xiaoping ,  SHIVER, John, W.

IPC分类号： A61K39/00

CPC分类号： A61K39/0007 ,  A61K2039/6068 ,  A61K2039/6087 ,  A61K2039/6093 ,  A61K2039/64

摘要： The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer’s disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

公开(公告)号：EP1940466A2

公开(公告)日：2008-07-09

申请号：EP06836346.4

申请日：2006-10-17

申请人： Merck & Co., Inc.

发明人： KINNEY, Gene ,  STROHL, William, R. ,  AN, Zhiqiang

IPC分类号： A61K39/395

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to antibodies that -differentially -recognize- -multi- dimensional conformations- of- Aβ- derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.